A biosensor platform based on Bloch Surface Waves and operating in angular interrogation mode is applied to the detection of a clinical biomarker (HER2-neu/ERBB2) related to breast cancer initiation/progression. Preparing regions for specific recognition of different proteins as well as a reference on the biochip enables to correct the signal for nonspecific effects. Additionally, label-free analysis and surface wave enhanced fluorescence detection can be applied and compared directly on the platform. Cell lysates with high and low expression levels of ERBB2 are analyzed. Comparing the signals of such ERBB2 positive and negative samples estimates the limit of detection at 1.7 ng/mL. This is well below the threshold of 15 ng/mL set by the FDA for clinically useful ERBB2 detection in human serum, demonstrating that 1DPC-based biochips are attractive candidates for breast cancer detection/monitoring.

Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection / Danz, Norbert; Sinibaldi, Alberto; Allegretti, Matteo; Sepe, Elisabetta; Munzert, Peter; Giacomini, Patrizio; Michelotti, Francesco. - 10685:(2018), p. 32. ((Intervento presentato al convegno SPIE Photonics Europe tenutosi a Strasbourg [10.1117/12.2306424].

Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection

Sinibaldi, Alberto
Secondo
;
SEPE, ELISABETTA;Michelotti, Francesco
Ultimo
2018

Abstract

A biosensor platform based on Bloch Surface Waves and operating in angular interrogation mode is applied to the detection of a clinical biomarker (HER2-neu/ERBB2) related to breast cancer initiation/progression. Preparing regions for specific recognition of different proteins as well as a reference on the biochip enables to correct the signal for nonspecific effects. Additionally, label-free analysis and surface wave enhanced fluorescence detection can be applied and compared directly on the platform. Cell lysates with high and low expression levels of ERBB2 are analyzed. Comparing the signals of such ERBB2 positive and negative samples estimates the limit of detection at 1.7 ng/mL. This is well below the threshold of 15 ng/mL set by the FDA for clinically useful ERBB2 detection in human serum, demonstrating that 1DPC-based biochips are attractive candidates for breast cancer detection/monitoring.
SPIE Photonics Europe
1D photonic crystals; Biosensor platform; ERBB2 tumor biomarker; surface wave enhanced fluorescence; Electronic, Optical and Magnetic Materials; Condensed Matter Physics; Computer Science Applications1707 Computer Vision and Pattern Recognition; Applied Mathematics; Electrical and Electronic Engineering
04 Pubblicazione in atti di convegno::04b Atto di convegno in volume
Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection / Danz, Norbert; Sinibaldi, Alberto; Allegretti, Matteo; Sepe, Elisabetta; Munzert, Peter; Giacomini, Patrizio; Michelotti, Francesco. - 10685:(2018), p. 32. ((Intervento presentato al convegno SPIE Photonics Europe tenutosi a Strasbourg [10.1117/12.2306424].
File allegati a questo prodotto
File Dimensione Formato  
paper116_SPIE_2018_Combined Label-free Fluorescence_ _ _.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 538.91 kB
Formato Adobe PDF
538.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1194191
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact